Stockreport

Should EMA's Conditional Nod for ANKTIVA in High-Risk Bladder Cancer Require Action From ImmunityBio (IBRX) Investors? [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF with BCG, to treat BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ in adults across the EU. This marks the first EMA-recommended immunotherapy fo [Read more]